Ovarian cancer is a lethal female malignancy with more than 14,000 deaths per year in United States. This is related to the fact that most patients are diagnosed at an advanced stage. While over the years there has been a focus on trying to diagnose this neoplasm in its earliest stages to improve outcomes; there has been an explosion of over 10 new FDA approved therapies during the last 15 years for this disease. However, outside of BRCA mutation status and PARP inhibitors, molecular markers to guide therapeutic decision making have been sparse.
In this special issue, authors will present studies focusing on molecular markers which improve early detection, prognostic predictions, and personalized therapies. Studies may also focus on how molecular markers predict cytoreductive surgery outcomes, and response to platinum-based chemotherapies and intra peritoneal therapy.
Special consideration will be given to studies focusing on prognosis or prediction of response to PARP inhibitors, immunotherapies, and treatments inhibiting angiogenesis. Reports investigating markers of the effectiveness of FDA approved drugs not yet approved for ovarian cancer may also be considered in this special issue.
Prof. Sharad Ghamande and Dr. David Mysona
Manuscript Submission Information
Manuscripts should be submitted online at https://ejgo.imrpress.combyregisteringandlogging into this website. Once you are registered,click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on theInstructions for Authorspage. European Journal of Gynaecological Oncology is an international peer-reviewed open access quarterly journal published by IMR Press.